US/UK/Canada

Share

Pick a time period -
Tags ( Active)

TiGenix selects TFS for the first clinical trial to treat severe sepsis with allogeneic expanded adipose-derived stem cells.

TiGenix has selected TFS International (TFS) for the first clinical trial (SEPCELL) to use stem cell therapy in the treatment of severe sepsis secondary to severe community acquired pneumonia (sCAP).The SEPCELL project is a randomized, double-blind, placebo-controlled, Phase Ib/IIa study in severe sepsis secondary to severe CAP (sCAP). Subjects in the trial must have sCAP requiring mechanical ventilation and/or vasopressors. The trial is expected to enroll 180 patients, and will be conducted at approximately 50 centers throughout Europe. Subjects will be randomized 1:1 to receive active

LobSor Pharmaceuticals and TFS report LECIGon® Achieving Its Primary Endpoint in a Pivotal EU Study for Advanced Parkinson’s Disease

· LobSor plans to submit its regulatory application for EU approval in early 2016 · LobSor in process of planning discussions with the U.S. Food and Drug Administration (FDA) to outline US path to commercialization LobSor Pharmaceuticals, a specialty pharmaceutical company based in Sweden, announced that LECIGon® has achieved its primary endpoint in a late-stage study examining the pharmacokinetics of LECIGon® compared to Abbvie’s Duodopa® in the treatment of advanced Parkinson’s disease. When comparing the levodopa bioavailability during daytime enteral infusion, LECIGon demonstrated

TFS and LobSor Pharmaceuticals advance their risk-sharing partnership in Parkinson’s disease to the clinics.

TFS and LobSor Pharmaceuticals (LobSor) have reached an important milestone in their risk-sharing partnership by advancing LobSor’s LECIGel® for Advanced Parkinson’s disease into the clinics.In June 2014, TFS and LobSor signed a risk-sharing agreement for the development of LobSor’s Advanced Parkinson’s disease candidate LECIGel® with the objective to file a Marketing Authorization (MA) in Europe. TFS is under the risk-sharing agreement responsible for the regulatory strategy, clinical development planning and execution including the regulatory MA filing. TFS and LobSor have advanced the

There are no items matching the current filter
There are no more items matching the current filter
Back to top